معرفی
Ralf Schittenhelm is a Professor (Research) in Biochemistry & Molecular Biology at Monash University, Australia. He leads the Monash Biomedical Proteomics Platform, providing mass spectrometry expertise. His academic career includes a PhD from the University of Zurich (Switzerland) and postdoctoral research at ETH Zurich and Monash University. Key roles include Director of the Proteomics Platform since 2016.
Education: BSc in Biochemistry from University of Bayreuth (Germany), PhD in Molecular Biology from University of Zurich (2009). Postdoctoral training at ETH Zurich (2009–2012) and Monash University (2012–2016).
Research Focus: Proteomics, metabolic disorders, cell cycle regulation, bacterial pathogenesis, and drug target discovery. Specializes in applying high-resolution mass spectrometry to study disease mechanisms (e.g., spondyloarthropathies, kidney diseases) and protein networks.
Notable projects include:
- Designing precision dietary therapies for metabolic disorders
- Metabolic landscape analysis of diabetic kidney disease
- Drug Target Identification Platform (funded by Australian Health Department)
Awards:
- Swiss National Science Foundation Fellowship (2012)
- Swiss Foundation for Grants in Biology and Medicine Fellowship (2013)
Collaborations span global institutions, with active projects in Australia, Europe, and Asia. His work aligns with UN Sustainable Development Goals related to health and innovation.
